Print

Bristol-Myers Squibb Company (BMY) to Spend $250 Million to Expand Biologics Facility, Increase Workforce by 350  
4/11/2013 8:40:06 AM

DEVENS, Mass.--(BUSINESS WIRE)-- Bristol-Myers Squibb (BMY) today announced plans for an approximately $250 million expansion of its large-scale biologics manufacturing facility in Devens, Massachusetts. The expansion will introduce biologics development and clinical trial manufacturing capabilities to the site, while adding approximately 350 employees to the Devens workforce over time.

“Biologics are increasingly important in the treatment of serious diseases and are a growing part of our company’s pipeline of potential new therapies,” said Lou Schmukler, president, Global Manufacturing & Supply. “This initiative is designed to accelerate the development of new biologics medicines through the closer alignment of biologics research and development, and manufacturing.”

Bristol-Myers Squibb plans to construct two new buildings on its 89-acre Devens campus. One will be dedicated to Process Development, a group that designs processes for early production of investigational biologics medicines. A second building will house Clinical Manufacturing, where investigational medicines will be produced to support clinical trials. Both represent new capabilities for Devens, a site that in its early years has focused solely on large-scale, bulk biologics manufacturing.

“This project represents a significant expansion in both the size and mission of Devens,” said Peter Moesta, senior vice president, Biologics Manufacturing and Process Development. “We envision Devens as a center of excellence for the development and manufacture of biologics medicines, optimally organized to support our growing pipeline of investigational medicines and potential new products.”

Together, the two buildings will add approximately 200,000 square feet of laboratory and office space to the Devens site, which is now comprised of six major buildings in a 400,000-square-foot complex.

Construction of the Devens site was completed in 2009. It was Bristol-Myers Squibb’s first major facility in Massachusetts and the largest capital investment in its history – $750 million – and helped signal the company’s transformation into a next-generation biopharmaceutical company. The Devens site also was designed to accommodate future expansion, and the decision to expand reflects both the initial success of Devens and some of the factors that first drew Bristol-Myers Squibb to the region. These include the abundance of biotechnology knowledge, education and training in the Boston area, which has created a large and well-qualified workforce, as well as the inception of the state’s Life Sciences initiative.

Work on the expansion is expected to begin in late 2013 and be completed in 2015. In the interim, Bristol-Myers Squibb has leased 30,000 square feet of laboratory space in nearby Hopkinton, Massachusetts, to begin moving some biologics process development functions closer to Devens during construction. The company intends to maintain this space until construction is completed.

Bristol-Myers Squibb Forward Looking Statement

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding plans to expand a biologics manufacturing facility that involves substantial risks and uncertainties. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the expansion of the facility will be completed, or if completed, will be completed on the timeline described in the release. There is also no guarantee that the completion of the expanded facility will receive the required regulatory approvals to accelerate production or that the number of employees expected to be added at the site will be so employed. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb’s business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2012, in our Quarterly Reports on Form 10-Q, and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about the company, visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

Contact:

Bristol-Myers Squibb

John Patella, 732-227-6197

john.patella@bms.com


//-->